Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Inventory (2016 - 2025)

Historic Inventory for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to $3.6 million.

  • Ocular Therapeutix's Inventory rose 1723.68% to $3.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 million, marking a year-over-year increase of 1723.68%. This contributed to the annual value of $3.6 million for FY2025, which is 1723.68% up from last year.
  • Per Ocular Therapeutix's latest filing, its Inventory stood at $3.6 million for Q4 2025, which was up 1723.68% from $3.5 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Inventory registered a high of $3.6 million during Q4 2025, and its lowest value of $1.1 million during Q2 2021.
  • In the last 5 years, Ocular Therapeutix's Inventory had a median value of $2.3 million in 2023 and averaged $2.2 million.
  • In the last 5 years, Ocular Therapeutix's Inventory surged by 144.53% in 2021 and then surged by 6686.3% in 2023.
  • Over the past 5 years, Ocular Therapeutix's Inventory (Quarter) stood at $1.2 million in 2021, then skyrocketed by 57.92% to $2.0 million in 2022, then increased by 16.77% to $2.3 million in 2023, then skyrocketed by 31.89% to $3.0 million in 2024, then grew by 17.24% to $3.6 million in 2025.
  • Its Inventory stands at $3.6 million for Q4 2025, versus $3.5 million for Q3 2025 and $3.0 million for Q2 2025.